Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate

Author: Benzinga Newsdesk | November 13, 2025 07:37am
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 50 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $19.066 million which beat the analyst consensus estimate of $18.635 million by 2.31 percent. This is a 742.51 percent increase over sales of $2.263 million the same period last year.

Posted In: XLO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist